{"filing":{"accession_number":"0001599298-26-000067","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"smmt-20260723.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/smmt-20260723.htm"},"events":[{"id":20044,"run_id":18046,"accession_number":"0001599298-26-000067","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Summit Therapeutics issued a press release on July 23, 2026 announcing Q2 2026 financial results and operational progress, including GAAP and Non-GAAP operating expenses, net loss, cash position of $690.7 million, and significant clinical progress on ivonescimab including positive HARMONi-6 overall survival data.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19301,"accession_number":"0001599298-26-000067","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Summit Therapeutics issued a press release on July 23, 2026 announcing financial results and operational progress for Q2 2026 ended June 30, 2026, disclosing GAAP and Non-GAAP operating expenses, R\u0026D expenses, G\u0026A expenses, net loss, and cash position ($690.7 million). The filing explicitly states this is an Item 2.02 disclosure of \"Results of Operations and Financial Condition\" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:27.161970+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19302,"accession_number":"0001599298-26-000067","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces that Summit will utilize slides during an earnings call scheduled for July 23, 2026 to announce its second quarter 2026 financial results and provide an operational update. The attached Exhibit 99.1 is a comprehensive earnings release reporting Q2 2026 financial results (GAAP and Non-GAAP operating expenses, R\u0026D expenses, G\u0026A expenses, and net loss), cash position ($690.7 million), and significant clinical progress on ivonescimab including positive HARMONi-6 overall survival data and updated HARMONi analysis. This is a material earnings disclosure affecting investor assessment of the company's financial condition and clinical development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:27.161970+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19301,"accession_number":"0001599298-26-000067","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Summit Therapeutics issued a press release on July 23, 2026 announcing financial results and operational progress for Q2 2026 ended June 30, 2026, disclosing GAAP and Non-GAAP operating expenses, R\u0026D expenses, G\u0026A expenses, net loss, and cash position ($690.7 million). The filing explicitly states this is an Item 2.02 disclosure of \"Results of Operations and Financial Condition\" with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:27.161970+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-23"},{"id":19302,"accession_number":"0001599298-26-000067","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure announces that Summit will utilize slides during an earnings call scheduled for July 23, 2026 to announce its second quarter 2026 financial results and provide an operational update. The attached Exhibit 99.1 is a comprehensive earnings release reporting Q2 2026 financial results (GAAP and Non-GAAP operating expenses, R\u0026D expenses, G\u0026A expenses, and net loss), cash position ($690.7 million), and significant clinical progress on ivonescimab including positive HARMONi-6 overall survival data and updated HARMONi analysis. This is a material earnings disclosure affecting investor assessment of the company's financial condition and clinical development progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:12:27.161970+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-07-23"}]}